InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.240 0.485 (64.24%)+
Announcement
Release
2 Jul 2026 8:46AM
Price at Release
$0.755
Full Release
download
Summary
OncoSil Medical Limited has been selected to participate in the PALACROS consortium, a major European academic initiative aimed at advancing treatment for patients with unresectable locally advanced pancreatic cancer (LAPC). The company will conduct the PULSE Phase II clinical study, a multi-centre, randomised trial involving 120 patients across five European centres, evaluating the OncoSil™ device for repeat treatment in LAPC. The study offers significant cost savings due to in-kind provision of device treatments and aims to enhance local tumour control, potentially increasing the number of patients eligible for curative surgery. If successful, the trial outcomes could lead to increased adoption of OncoSil™ as a standard treatment, with potential commercial benefits.
Key Points
  • OncoSil Medical is participating in the PALACROS consortium, a European initiative focused on improving outcomes for patients with unresectable locally advanced pancreatic cancer (LAPC).
  • OncoSil Medical will conduct the PULSE Phase II clinical study, evaluating repeat OncoSil treatment in 120 patients with unresectable, non-progressive LAPC following chemotherapy.
  • The OncoSil device treatments are provided in-kind for the trial, resulting in significant cost savings compared to a company-sponsored study.
  • The study aims to improve local tumour control and potentially increase the number of patients eligible for curative surgery.
  • Key study endpoints include local progression-free survival, overall survival, safety, quality of life, and health economic analysis.
  • OncoSil Medical expects potential commercial benefits from the clinical data resulting from the trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.